Difference between interferon beta 1a and 1b

Common Questions and Answers about Difference between interferon beta 1a and 1b

rebif

I was a 1a and a 1b and beat them both......just consider a 1 a 1 and treat it as aggressively as you can.

I started out at the very beginning with genotype 1A and 1B. After many, many treatments, I finally cleared the 1B, but the 1A has remained resistant to the 10 treatments that I've tried. As NYGirl said above, it depends on the individual and how that person's immune system handles it.

From the patient’s perspective there is little difference between subspecies; both are managed similarly.

All Genotypes 1's are harder to clear. I had both 1A and 1B and I was able to clear 1B after several heavy duty treatments, but my 1A remains the stubborn one, in my body, after 9 treatments!!!! Go figure!

When comparing the IFN genes between 1b-RVR and 1b-nonRVR, 1b-RVR showed a more significant induction of IFN genes than 1b-nonRVR. All patients with genotype 2a showed rapid response to IFN, although induction of IFN genes was not as high as 1b-RVR, suggesting that other factors might be involved in the IFN sensitivity of genotype 2a.

I am cirrhotic, 1A, and failed both single Interferon (when stage 1) and double Inter/Ribaviron (when stage 2) tx's over the years. This time around (2011-12) with triple tx. my Incivek was abreviated from the standard 12 weeks to 9-10 weeks because of side effects (primarily anemia). The remaining Interferon and Ribavirin. was much much easier to tolerate for the rest of the 48 weeks. I became undetectable 3 weeks into therapy and remained undetectable 7 months post tx a.k.a.

The meds in 94-95 were tepid then, and gave the virus the chance to mutate between injections. The pegalated interferon lasts in your body so much longer in comparison.....

Hi everyone! I was looking at frijole's spreadsheets and was interested in doing one myself. (I am sure Frijole has enough going on to add more to the list)! I was interested in knowing everyone's Pre-tx viral load, and if you are a 1 please distinguish between a & b, and your phenotype (cc, ct, tt). This is just for my own curiosity and I would appreciate your feedback. Thanks to everyone and have a great day!

We were discussing if he should wait for the combo pill with no interferon and ribavirin. He did SOC a few years ago and did really bad on the interferon and Riba for 48 weeks. What do you think? I called my clinic to see if I could get him in the BMS trial but waiting list is really long. I suggested he call his Dr on test result, and talk further. He goes to Kaiser and was sent results with no follow through. Going to a .53 to .86 in one year is a big jump.

also an important ratio difference in 1a and 1b concerning Telaprevir resistance and mutant strains in Telaprevir treatment failure subjects.

Hi there and I am a 1b and cleared over two years ago with interferon & Riba...I have a PCR every 6 months to check I am still clear as my hubby has HepC he is geno 1a...

66-70% for 1b vs. 59 -63 % for 1a The above reflects results for treatment naive patients and irrespective of other facors involved.... I will copy the data article later so you are not talking my word for it busy at the moment tho..

http://www.fiercebiotech.com/story/year-after-11b-buyout-gilead-track-blockbuster-hep-c-program/2013-01-07?utm_source=rss&utm_medium=rss This is all I could find so far...

I am no expert, but since three of the CRAB drugs are interferon beta (either 1a or 1b), they should all have the similar benefits/risks.

The link to the official press release is here: http://www.aan.com/press/index.cfm?fuseaction=release.view&release=1061 The U.S. News article confused me, because interferon beta-1a is available in the U.S. (as Avonex and Rebif). However, the official release clarifies that "the trial was conducted with the human serum albumin-free formulation of interferon beta-1a," and that isn't available in the U.S.

This suggests to me that genotype 1 may need to be cleaved further into 1a/1b subtype distinctions for future clinical trials, and I can envision that DAA regimens may even be tailored to HCV subtype. In current practice, we routinely obtain subtype information with our genotype assays, so no additional information generally needs to be requested.

Recommended